Psychiatric and cardiometabolic disorders are associated through bidirectional and overlapping pathways involving chronic low-grade inflammation, HPA axis dysregulation, insulin resistance, and sleep/circadian disturbance.
This narrative review synthesizes evidence that psychiatric disorders (depression, anxiety, schizophrenia, SMI) and cardiometabolic disease share bidirectional biological pathways, including inflammation, HPA axis dysregulation, insulin resistance, oxidative stress, mitochondrial dysfunction, altered brain energy metabolism, gut microbiome disruption, and sleep/circadian disturbance. The review emphasizes that metabolic dysfunction may worsen psychiatric symptoms and vice versa, supporting integrated care and routine metabolic screening.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Psychiatric and cardiometabolic disorders are associated through bidirectional and overlapping pathways involving chronic low-grade inflammation, HPA axis dysregulation, insulin resistance, and sleep/circadian disturbance. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Psychiatric and cardiometabolic disorders are associated through bidirectional and overlapping pathways involving chronic low-grade inflammation, HPA axis dysregulation, insulin resistance, and sleep/circadian disturbance.
This conclusion is most relevant to: Individuals with psychiatric disorders (depression, anxiety, schizophrenia, severe mental illness) and cardiometabolic disease (obesity, insulin resistance, diabetes, dyslipidemia, hypertension, cardiovascular disease).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Metabolic Dysfunction in Psychiatric Disorders: A Narrative Review of Shared Pathways Between Mental Illness and Cardiometabolic Disease. (Cureus, 2026) —
How It Works
The proposed biological pathway:
- ▸Chronic low-grade inflammation and HPA axis dysregulation are activated in both psychiatric and cardiometabolic disorders
- ▸Insulin resistance, oxidative stress, and mitochondrial dysfunction impair brain energy metabolism
- ▸Gut microbiome disruption and sleep/circadian disturbance further exacerbate metabolic and psychiatric symptoms
- ▸Result: Bidirectional worsening of psychiatric and cardiometabolic outcomes
Who Might Benefit
Evidence fit by population:
- ▸Individuals with psychiatric disorders (depression, anxiety, schizophrenia, severe mental illness) and cardiometabolic disease (obesity, insulin resistance, diabetes, dyslipidemia, hypertension, cardiovascular disease)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Narrative review design limits systematic assessment of evidence quality and may introduce selection bias
- ▸Causality cannot be established due to lack of longitudinal or interventional data in the reviewed studies
Frequently Asked Questions
What are the main shared pathways between psychiatric disorders and cardiometabolic disease?▼
The review identifies chronic low-grade inflammation, HPA axis dysregulation, insulin resistance, oxidative stress, mitochondrial dysfunction, altered brain energy metabolism, gut microbiome disruption, and sleep/circadian disturbance as key shared pathways.
Does metabolic dysfunction precede psychiatric symptoms or vice versa?▼
The evidence suggests bidirectional relationships; metabolic changes may precede long-term treatment exposure in psychotic disorders, while psychiatric illness can increase cardiometabolic risk through stress biology, lifestyle factors, and medication effects.
What clinical recommendations does the review support?▼
The review supports routine metabolic screening, early risk stratification, individualized psychotropic prescribing, lifestyle intervention, and integrated care involving psychiatry, primary care, endocrinology, cardiology, nutrition, and behavioral health services.
Are antipsychotic medications the main cause of metabolic dysfunction in psychiatric patients?▼
Antipsychotic-associated weight gain and glucose-lipid abnormalities are important, but metabolic changes may also occur before long-term treatment exposure, particularly in psychotic disorders, indicating shared underlying mechanisms.
References
- 1.Mohanty P, Uddin M, Sambhav K, S S, Lodha N, Anand A, Basu S. “Metabolic Dysfunction in Psychiatric Disorders: A Narrative Review of Shared Pathways Between Mental Illness and Cardiometabolic Disease..” Cureus, 2026. PMID: 42502529 DOI: 10.7759/cureus.111469